Clinical trial
A Multi-center, Long-term, Open-label Extension Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia
NCT00754221 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Long-term, Open-label Extension Study of [S,S]-Reboxetine (PNU-165442G) Administered Once Daily in Patients With Fibromyalgia
- Lead sponsor
- Pfizer
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- May 31, 2008
- Completion date
- May 31, 2009
- Enrollment
- 390 (actual)
- Sites
- 109
Conditions
As the registry lists them; a condition with its own page is linked.